Project Overview

A leading global biopharma company engaged us to explore the commercial outlook for an innovative EGFR-targeted treatment in four Asia-Pacific oncology hubs—Singapore, South Korea, Hong Kong, and Taiwan. Rapid policy reforms in these markets have accelerated access to novel therapies, prompting the need for fresh insight into physician mind-sets, unmet needs, and potential uptake among patients with locally advanced or metastatic NSCLC. Roughly 200 oncology specialists were consulted through a blend of qualitative and quantitative research.

Key Learning Objectives

• Unmet Clinical Needs – Clarify therapeutic gaps for patients who progress after EGFR-TKI therapy.

• Decision Drivers – Understand how efficacy markers (ORR, PFS), safety considerations, and reimbursement dynamics shape prescribing choices.

• Market Sizing – Estimate the eligible patient pool and forecast penetration by mutation subtype and disease stage.

• Attribute Trade-offs – Determine which product features most powerfully influence commercial opportunity in competitive landscapes.

Methodology

• In-depth Interviews – One-on-one discussions with senior thoracic and medical oncologists in each market to uncover nuanced prescribing logic and future expectations.

• Online Survey – A structured questionnaire reaching nearly 180 additional healthcare practitioners to validate hypotheses and quantify demand signals.

• Integrated Analytics – Combined findings translated into scenario models that factor in national reimbursement schemes and evolving clinical guidelines.

Key Deliverables

• Opportunity Map detailing country-specific patient volumes, uptake curves, and competitive positioning.

• Physician Insight Report highlighting adoption triggers, barriers, and attribute preference weights.

• Strategic Playbook offering actionable launch recommendations—including pricing corridors, medical-education priorities, and resource-allocation scenarios—aligned with pending regulatory review timelines.